UGT1A1 and metastatic colorectal cancer: One CUA with model-based study from France [71] and one CEA with model-based study from the US [72] were performed to evaluate the cost-effectiveness of UGT1A1 screening before prescribing irinotecan to prevent severe neutropenia in metastatic colorectal cancer.